Literature DB >> 15479813

A novel approach for producing lentiviruses that are limited to a single cycle of infection.

David T Evans1, Jennifer E Bricker, Ronald C Desrosiers.   

Abstract

We have devised a novel approach for producing simian immunodeficiency virus (SIV) strains and, potentially, human immunodeficiency virus type 1 (HIV-1) strains that are limited to a single cycle of infection. Unlike previous lentiviral vectors, our single-cycle SIV is capable of expressing eight of the nine viral gene products and infected cells release immature virus particles that are unable to complete subsequent rounds of infection. Single-cycle SIV (scSIV) was produced by using a two-plasmid system specifically designed to minimize the possibility of generating replication-competent virus by recombination or nucleotide reversion. One plasmid carried a full-length SIV genome with three nucleotide substitutions in the gag-pol frameshift site to inactivate Pol expression. To ensure inactivation of Pol and to prevent the recovery of wild-type virus by nucleotide reversion, deletions were also introduced into the viral pol gene. In order to provide Gag-Pol in trans, a Gag-Pol-complementing plasmid that included a single nucleotide insertion to permanently place gag and pol in the same reading frame was constructed. We also mutated the frameshift site of this Gag-Pol expression construct so that any recombinants between the two plasmids would remain defective for replication. Cotransfection of both plasmids into 293T cells resulted in the release of Gag-Pol-complemented virus that was capable of one round of infection and one round of viral gene expression but was unable to propagate a spreading infection. The infectivity of scSIV was limited by the amount of Gag-Pol provided in trans and was dependent on the incorporation of a functional integrase. Single-cycle SIV produced by this approach will be useful for addressing questions relating to viral dynamics and viral pathogenesis and for evaluation as an experimental AIDS vaccine in rhesus macaques.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479813      PMCID: PMC523244          DOI: 10.1128/JVI.78.21.11715-11725.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 2.  Lentivirus vectors: difficulties and hopes before clinical trials.

Authors:  T Kafri
Journal:  Curr Opin Mol Ther       Date:  2001-08

3.  The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: cotranslational RNA encapsidation and limitation of Gag protein confer specificity.

Authors:  S D Griffin; J F Allen; A M Lever
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Generation of replication-defective helper-free vectors based on simian immunodeficiency virus.

Authors:  S S Kim; N Kothari; X J You; W E Robinson; T Schnell; K Uberla; H Fan
Journal:  Virology       Date:  2001-03-30       Impact factor: 3.616

6.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

7.  Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

Authors:  Y Wu; J W Marsh
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

8.  Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.

Authors:  J Hu; M B Gardner; C J Miller
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

Review 10.  Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective.

Authors:  Michael Louie; Martin Markowitz
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 5.970

View more
  20 in total

1.  Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha.

Authors:  Ruchi M Newman; Laura Hall; Michelle Connole; Guo-Lin Chen; Shuji Sato; Eloisa Yuste; William Diehl; Eric Hunter; Amitinder Kaur; Gregory M Miller; Welkin E Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

2.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

3.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

4.  Possible applications for replicating HIV 1 vectors.

Authors:  Atze T Das; Rienk E Jeeninga; Ben Berkhout
Journal:  HIV Ther       Date:  2010-05-01

5.  Controlling Multicycle Replication of Live-Attenuated HIV-1 Using an Unnatural Genetic Switch.

Authors:  Zhe Yuan; Nanxi Wang; Guobin Kang; Wei Niu; Qingsheng Li; Jiantao Guo
Journal:  ACS Synth Biol       Date:  2017-01-30       Impact factor: 5.110

6.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

7.  Atraumatic oral spray immunization with replication-deficient viral vector vaccines.

Authors:  Christiane Stahl-Hennig; Seraphin Kuate; Monika Franz; You S Suh; Heribert Stoiber; Ulrike Sauermann; Klara Tenner-Racz; Stephen Norley; Ki S Park; Young C Sung; Ralph Steinman; Paul Racz; Klaus Uberla
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

8.  Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.

Authors:  Jean D Boyer; Tara M Robinson; Michele A Kutzler; Gordon Vansant; David A Hokey; Sanjeev Kumar; Rose Parkinson; Ling Wu; Maninder K Sidhu; George N Pavlakis; Barbara K Felber; Charles Brown; Peter Silvera; Mark G Lewis; Joseph Monforte; Thomas A Waldmann; John Eldridge; David B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

9.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.